Story thread · 2 reports / 2 sources
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
financialpost.com · 1d
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO® 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated […]
First report: Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update — thestar.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.